| Main Stage B | October 13(Wed.) 10:20-11:00 |
|---|
| Department of Physics. Chuo University |
|
Y-h. Taguchi Professor |
Development of tensor decomposition based unsupervised feature extractionIn recent years, machine learning has been attracting a great deal of attention. Among them deep learning has a fatal flaw that it cannot perform ... |
| Main Stage B | October 13(Wed.) 12:50-13:00 |
|---|
| MOLCURE |
|
Satoshi Tamaki, Ph.D. CSO |
AI-driven peptide/antibody molecular design - Collaborative drug discovery pipeline portfolio |
| Main Stage B | October 13(Wed.) 13:20-13:40 |
|---|
| SyntheticGestalt |
|
Naoya Suzuki Principal, Business Development |
AI Lab: Digital Approaches For Drug Discovery & Life Science Research |
| Presentation Stage C | October 13(Wed.) 13:10-13:40 |
|---|
| Systems Pharmacology Mie University Graduate School of Medicine |
|
Toshio Tanaka Professor |
Patient-Derived Cancer Xenograft Zebrafish Model (PDXZ) for Drug Discovery Screening and Personalized MedicineThe U.S. National Cancer Institute has been using bank-derived cell lines for drug screening for many years, but due to the lack of clinical efficacy ... |
| Presentation Stage C | October 13(Wed.) 13:45-14:15 |
|---|
| SPERA PHARMA |
|
Hideaki Yamada Analytical Development Laboratory Associate Director |
Overview and Trends of Analytical Methods and Specifications Required for Development and Quality Control of Monoclonal Antibody DrugsMonoclonal antibody (mAb) drugs are valid therapeutics due to their high target specificity and have provided huge market value in recent years. mAb molecules are ... |
| Presentation Stage D | October 13(Wed.) 10:20-10:50 |
|---|
| Twist Bioscience |
|
Takeshi Kawai Business Development Manager |
Writing the Future: Antibody Development Tools to Enable Your Best Research IdeasTwist Bioscience (TWIST), based in California, U.S.A., offers many products such as synthetic genes, oligo pools, enrichment for NGS targeted resequencing probes, based on its ... |
| Presentation Stage D | October 13(Wed.) 11:30-12:00 |
|---|
| JSR Corporation |
|
Life Sciences Deaprtment |
JSR Bioprocess ProductsJSR supplies protein A affinity chromatography resin, Amsphere A3, which is used in downstream processing to refine antibody drugs. We will introduce the application example ... |
| Presentation Stage D | October 13(Wed.) 12:05-12:35 |
|---|
| Space BD |
|
Shun Yamaguchi Life Science R&D Project Manager, Business Development |
Rapid and Efficient Drug Discovery by Microgravity × Crystallography - A Innovative Structure Based Drug Design Platform Provided by Space BD Inc. as the only private partner with JAXA.Space BD Inc. provide a service of space experiments under the microgravity of the International Space Station to obtain high-quality crystals which can improve the ... |
| Presentation Stage D | October 13(Wed.) 12:40-13:10 |
|---|
| [medU-net] Kumamoto University |
|
Shingo Ito |
Development of blood-tissue barrier permeable macromolecular drugs and nanocarrier using cyclic peptidesMacromolecular drugs cannot cross blood-tissue barriers composed of epithelial cells and vascular endothelial cells. Engineering of drug delivery system capable of effective macromolecular compound transcytosis ... |
| Presentation Stage D | October 13(Wed.) 13:15-13:45 |
|---|
| ASAHI KASEI CORPORATION |
|
Toru Katsumata New Product Development Office, Functional Additives Division |
"Hyaluronic Acid Nanogel" as a New Pharmaceutical Excipient For Long-Acting InjectionWe will introduce various functions of "Hyaluronic Acid Nanogel", which is a new pharmaceutical excipient. In this seminar, we will explain in detail the stabilization, ... |
| Presentation Stage D | October 13(Wed.) 15:00-15:30 |
|---|
| Waseda University |
Approaching to increase the use of the paretic hand by stimulated to the brain: The new concept of stroke rehabilitationThe hemiparetic hand due to stroke gets recovered by the rehabilitation to teat it. However, it is rare to get recovered completely from the paralysis, ... |
| Presentation Stage D | October 13(Wed.) 15:35-16:05 |
|---|
| Technology Research Association for next-generation natural products chemistry |
|
Kazuo Shinya |
Modification of complexed natural compounds by module editing technology and screening of natural compoundsNatural compounds have long been used as a resource for the development of pharmaceuticals and agrochemicals because of their potent activities and complex structures that ... |
| Presentation Stage D | October 13(Wed.) 16:10-16:40 |
|---|
| The Center for Open Innovation, Tokyo University of Pharmacy and Life Sciences |
|
Yoichi Negishi Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy |
Development of Ultrasound Responsive Nanobubbles for Nucleic Acid and Gene Delivery and its applicationIn recent years, the development of genetic drugs (siRNA, mRNA, or plasmid DNA etc) has been actively pursued as a new treatment for intractable diseases ... |
| Presentation Stage E | October 13(Wed.) 10:20-10:50 |
|---|
| [medU-net] Fukushima Medical University |
|
Kitazume Shinobu School of Health Sciences Professor |
1. Development of novel Alzheimer's model mice with robust CAA pathology 2. PTPRZ is a prominent diagnostic marker and therapeutic target of glioma |
| Presentation Stage E | October 13(Wed.) 10:55-11:25 |
|---|
| Kumamoto University Useful and Unique Natural Products for Drug Discovery and Development (UpRod) |
|
Tsuyoshi Shuto Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University / Associate Professor |
Exploring medicinal seeds from natural products by the next-generation research platform of drug discovery in Kumamoto UniversityIn the 1980s, medicinal seeds were explored from natural products, but later shifted to other modalities such as chemical compounds. However, in recent years, with ... |
| Presentation Stage E | October 13(Wed.) 12:05-12:35 |
|---|
| [medU-net] Shiga University of Medical Science |
|
Masahiro Matsuura Academia-Industry Collaboration Section, Research Promotion Office |
Introduction of Research Seeds and Medical Needs at Shiga University of Medical ScienceWe will introduce our research seeds and medical needs of Shiga University of Medical Science. We look forward to collaboration with possible enterprises. |
| Presentation Stage E | October 13(Wed.) 13:15-13:45 |
|---|
| [medU-net] Nagasaki University |
|
Hitoshi Sasaki Professor, Institute of Tropical Medicine |
Development of inhaled mRNA vaccine nano-ball against SARS-CoV-2We have developed a novel inhaled mRNA vaccine nano-ball against SARS-CoV-2. We constructed several mRNA encoding SARS-CoV-2 antigen proteins and encapsulated those mRNA into nano-ball. ... |
| Presentation Stage E | October 13(Wed.) 13:50-14:20 |
|---|
| Department of Pharmacology, Kochi Medical School, Kochi University |
|
Nakamura Rina |
| Presentation Stage E | October 13(Wed.) 15:35-16:05 |
|---|
| [medU-net] Yamaguchi University Graduate School of Medicine |
|
Issei Saeki Department of Gastroenterology and Hepatology |
Development of an easy and low-cost screening test using high sensitive DNA methylation analysis for diagnosing hepatocellular carcinoma |
| Presentation Stage E | October 13(Wed.) 16:10-16:40 |
|---|
| [medU-net] Yamaguchi University Graduate School of Medicine |
|
Kensuke Shibata |
Establishment of immunotherapeutic strategy targeting tumor-derived metabolitesWe established a high-throughput screening approach and identified a tumor-derived metabolite as a ligand for T cells. The tumor-derived ligand had a therapeutic potential in ... |
| Main Stage B | October 14(Thu.) 15:00-15:20 |
|---|
| SyntheticGestalt |
|
Naoya Suzuki Principal, Business Development |
AI Lab: Digital Approaches For Drug Discovery & Life Science Research |
| Main Stage B | October 14(Thu.) 15:30-15:40 |
|---|
| HACARUS INC |
|
Kenshin Fujiwara |
Diagnostic and Drug Discovery Support by AI without Big Data |
| Presentation Stage C | October 14(Thu.) 12:35-12:50 |
|---|
| Nagoya University |
|
Hiromasa Tanaka Center for Low-temperature Plasma Sciences, Professor |
Development of plasma-activated solutionsWe have previously developed low-temperature plasma with high electron density, and we applied for cancer treatments. We have found that plasma-irradiated solutions exhibited anti-tumor effects ... |
| Presentation Stage C | October 14(Thu.) 13:10-13:40 |
|---|
| KAGOSHIMA UNIVERSITY |
Introducing the seeds of Kagoshima University |
| Presentation Stage C | October 14(Thu.) 15:20-16:20 |
|---|
| Fukuoka Prefectural Bio Industry Center Promotion Conference |
Achievements of The Fukuoka Bio Valley ProjectThe Fukuoka Bio Valley Project is promoting the creation of a bio-industry in the region centered on Kurume City, which is a core city in ... |
| Presentation Stage D | October 14(Thu.) 10:20-10:50 |
|---|
| [medU-net] Kumamoto University |
|
Takeshi Masuda |
Development of single cell proteomics technologiesProteins play an essential role in our body. Observing the types and amounts of these proteins leads to an understanding of biological phenomenon. The research ... |
| Presentation Stage D | October 14(Thu.) 10:55-11:25 |
|---|
| Rentschler Biopharma |
|
Hidenori Ohara Representative Rentschler Biopharma |
Driving next-generation biopharmaceutical production from concept to market: Rentschler Biopharma, your trusted CDMO partner- Translating 50 years of experience and an outstanding track record into lifesaving therapeutics - Tailormade solutions for high-quality bioprocess development and clinical and commercial cGMP ... |
| Presentation Stage D | October 14(Thu.) 11:30-12:00 |
|---|
| ASAHI KASEI CORPORATION |
|
Toru Katsumata New Product Development Office, Functional Additives Division |
"Hyaluronic Acid Nanogel" as a New Pharmaceutical Excipient For Solubility EnhancerWe will introduce various functions of "Hyaluronic Acid Nanogel", which is a new pharmaceutical excipient. In this seminar, we will explain in detail the solubilization ... |
| Presentation Stage D | October 14(Thu.) 12:05-12:35 |
|---|
| The Noguchi Institute |
|
Mamoru Mizuno |
Synthesis of site-specific antibody-drug conjugates by one-pot glycan remodeling methodIn recent years, there has been a need to develop technology for the production of antibody-drug conjugates (ADCs) with high homogeneity and controlled drug-antibody ratio ... |
| Presentation Stage D | October 14(Thu.) 15:35-16:05 |
|---|
| Research Institute for Animal Science in Biochemistry and Toxicology / MARUBENI CHEMIX CORPORATION |
|
Inoue Takahiro Research and Business Promotion Division Researcher |
| Presentation Stage D | October 14(Thu.) 16:10-16:40 |
|---|
| [medU-net] SAPPORO MEDICAL UNIVERSITY |
|
YOSHIHIKO HIROHASHI |
| Presentation Stage E | October 14(Thu.) 10:20-10:50 |
|---|
| Tohoku University Tohoku Medical Megabank Organization |
|
Soichi Ogishima |
| Presentation Stage E | October 14(Thu.) 10:55-11:25 |
|---|
| Tokyo University of Science |
|
IWAKURA Yoichiro Research Institute for Biomedical Sciences, Professor |
Treatment of autoimmune diseases and bone metabolic diseases using CTRP6 and CTRP3Multiple sclerosis and IgA nephritis are typical autoimmune diseases without any effective drugs to treat except for symptomatic therapies. Development of effective drugs for osteoarthritis ... |
| Presentation Stage E | October 14(Thu.) 11:30-12:00 |
|---|
| [medU-net] Hamamatsu University School of Medicine |
|
Kosuke Shimizu Department of Molecular Imaging, Institute of Medical Photonics Research, Preeminent Medical Photonics Education & Research Center/Associate Professor |
Pharmaceutical technology for the treatment of immune diseases |
| Presentation Stage E | October 14(Thu.) 12:05-12:35 |
|---|
| Doshisha University, Graduate school of Life and Medical Sciences |
|
SAITO Naoto Associate Professor |
Development of Genetically Encoded Green Fluorescent cAMP probe which is suited for real-time analysisCyclic adenosine monophosphate (cAMP) is a major second messenger that mediates a wide variety of physiological responses such as metabolic regulation, cellular differentiation and neuronal ... |
| Presentation Stage E | October 14(Thu.) 13:50-14:05 |
|---|
| Nagoya University |
|
Akira TAZAKI Department of Occupational and Environmental Health, Lecturer |
Biomedical analysis focusing on melanin and melanocyteThe skin, including hair, is the primary organ which receives various external environmental stimuli. The amount of skin melanin changes due to external environmental stimuli ... |
| Presentation Stage E | October 14(Thu.) 14:25-14:55 |
|---|
| Kyoto University Medical Science and Business Liaison Organization |
|
SUZUKI SHINOBU Professor |
From Clinical Needs to Drug Discovery: Introduction of the Drug Discovery Co-Creation ProgramThese days, the technology for analyzing diseased tissues at the single cell level has made remarkable progress, and clinical research has been revolutionized by the ... |
| Presentation Stage E | October 14(Thu.) 16:10-16:40 |
|---|
| Tohoku University |
|
NAGAI Nobuhiro Assistant professor |
Development of controlled drug release device for posterior segment eye diseases and its clinical application |
| Main Stage A | October 15(Fri.) 15:30-15:40 |
|---|
|
ADSTEC Corporation
(Presentation in English)
Japan Bioindustry Association |
|
David Hild |
HPLC Buffers and Columns That Contribute to Producing mRNA Therapeutics & Vaccines |
| Main Stage B | October 15(Fri.) 13:35-13:45 |
|---|
| MOLCURE |
|
Satoshi Tamaki, Ph.D. CSO |
AI-driven peptide/antibody molecular design - Collaborative drug discovery pipeline portfolio |
| Presentation Stage C | October 15(Fri.) 10:20-10:50 |
|---|
| [medU-net] Kumamoto University |
|
Seiji Okada |
Establishment and application of novel immunodeficient mice optimized for human stem cell/cancer research.Development of novel strains of immunodeficient mice has evolutionally begun to provide the opportunity to utilize mice model for the study of human specific diseases ... |
| Presentation Stage C | October 15(Fri.) 11:30-12:00 |
|---|
| Institute for Glyco-core Research (iGCORE), Nagoya University and Gifu University, Tokai National Higher Education and Research system |
|
Jun Hirabayashi |
| Presentation Stage C | October 15(Fri.) 12:05-12:35 |
|---|
| Yokohama City University |
|
Nobuhiko Kojima Associate professor |
| Presentation Stage C | October 15(Fri.) 12:40-13:10 |
|---|
| Aoyama Gakuin University |
|
Hiromi Hirata, Makoto Kahima |
| Presentation Stage C | October 15(Fri.) 15:00-15:30 |
|---|
| SMC Laboratories (Presentation in English) |
|
Bui Phuong Linh |
STAM is the world's first mouse model for spontaneous liver cancer from a chronic liver disease "NASH".SMC introduce NASH (Non-Alcoholic Steatohepatitis) -Liver Cancer Mouse Model "STAM " originally developed by SMC. This model has the background of late-stage type 2 diabetes and ... |
| Presentation Stage C | October 15(Fri.) 15:35-16:05 |
|---|
| Oita University |
Cancer biomarkers for clinical application: new diagnostic markers for onset risks or prognosis |
| Presentation Stage D | October 15(Fri.) 10:20-10:50 |
|---|
| OSAKA CITY UNIVERSITY |
|
Takeshi Nakanishi Department of Applied Chemistry and Bioengineering Graduate School of Engineering Associate Professor |
Development of a novel format for IgG-shaped bispecific antibodiesBispecific antibodies have been energetically developed as next-generation biologics. To date, various forms of bispecific antibodies that are different from conventional IgG have been generated; ... |
| Presentation Stage D | October 15(Fri.) 10:55-11:25 |
|---|
| ASAHI KASEI CORPORATION |
|
Toru Katsumata New Product Development Office, Functional Additives Division |
"Hyaluronic Acid Nanogel" as a New Pharmaceutical Excipient For Long-Acting InjectionWe will introduce various functions of "Hyaluronic Acid Nanogel", which is a new pharmaceutical excipient. In this seminar, we will explain in detail the stabilization, ... |
| Presentation Stage D | October 15(Fri.) 11:30-12:00 |
|---|
| Kurume University |
|
Dr. Hironori Koga Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University |
Biomarker for early detection of pancreatic cancer by the pancreatic juice-derived exosomal microRNAsWe identified novel tumor-specific exosomal microRNAs from pancreatic juice of patients with pancreatic ductal adenocarcinoma. The discovered microRNA has high potential as a serum biomarker ... |
| Presentation Stage D | October 15(Fri.) 12:40-13:10 |
|---|
| KISHI KASEI |
|
Hisaya Nakazato pharmaceutical division |
| Presentation Stage D | October 15(Fri.) 13:15-13:45 |
|---|
| - Host: Eurofins Analytical Science Laboratories- Guest: Pharmatelier Inc. |
|
Guest Speaker, Mr. Motoyoshi Okamura President |
Current status and future prospects of CRO business related to biopharmaceuticals in Japan and overseasBiopharmaceutical tests are classified into drug substance, drug product release test and process control test, test method validation, characteristic analysis using dedicated analytical equipment, virus ... |
| Presentation Stage D | October 15(Fri.) 13:50-14:20 |
|---|
| National Institute of Genetics |
|
Mutszuaki Suzuki Director, NIG INNOVATION |
Introduction of research summary and research profiles at National Institute of GeneticsNational Institute of Genetics receives international acclaim in the field of life sciences. I would like to introduce some research tools developed at our institute ... |
| Presentation Stage D | October 15(Fri.) 14:20-14:50 |
|---|
| National Institute of Genetics |
|
Ken Kurokawa / Hiroshi Mori Advanced Genomics Center |
Advanced microbiome analysis at National Institute of Genetics |
| Presentation Stage D | October 15(Fri.) 15:00-15:30 |
|---|
| MSD K.K. , D3 LLC |
|
Koji Yashiro(MSD/BD&L Director), Tomoya Nagata(D3 LLC/CEO) |
Transforming Japanese innovation into global medicineFor decades, many innovations incepted at academic institutes in Japan have given rise to new drugs contributing to the health of people around the world. ... |
| Presentation Stage E | October 15(Fri.) 10:35-10:50 |
|---|
| Showa University |
|
Noriko Hida Division of Clinical Research and Development, Department of Clinical Pharmacy, Showa University / Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics Associate Professor |
Accelerating Clinical Trials of New Formulation Technologies - Formulation Research Team from Showa UniversityWe are collaborating with the Department of Pharmaceutics to organize clinical studies, such as clinical trials aimed at improving the ease of taking medicine for ... |
| Presentation Stage E | October 15(Fri.) 10:55-11:25 |
|---|
| Waseda University |
MHC-I recognition and promotion or inhibition of the elimination of abnormal cells by epithelial cellsWhen abnormal cells, such as oncogenically transformed cells and infected cells, occur in cell monolayers, normal allogeneic cells recognize and remove them. It is expected ... |
| Presentation Stage E | October 15(Fri.) 11:30-12:00 |
|---|
| [medU-net] NIIGATA UNIVERSITY |
|
KAWACHI Hiroshi Graduate School of Medical and Dental Sciences, Kidney Research Center, Professor |
Novel markers for differental diagnosis of nerhotic syndromeProteinuria, a major symptom of kidney diseases, enhances the progression of kidney diseases. The chronic kidney disease (CKD) patients with proteinuria have about 3 times ... |
| Presentation Stage E | October 15(Fri.) 13:50-14:20 |
|---|
| Metropolitan Academic Research Consortium |
|
Masahiko Kuroda |
| Presentation Stage E | October 15(Fri.) 15:00-15:30 |
|---|
| [medU-net] NIIGATA UNIVERSITY |
|
SUGAI Akihiro Brain Research Institute, Center for Bioresources, Assistant Professor |
An antisense nucleotide that enhances splicing of TDP-43 exitron for patients with TDP-43 proteinopathyWe present here an antisense nucleotides (ASO) that enhance the alternative splicing of TDP-43, a pathogenic protein in amyotrophic lateral sclerosis (ALS). TDP-43 is an ... |
| Main Stage A | October 13(Wed.) 13:50-14:20 |
|---|
| CellSeed |
|
Representative Board Director and President/CEO Setsuko Hashimoto, Ph.D. |
| Presentation Stage C | October 13(Wed.) 10:40-10:50 |
|---|
| Minaris Regenerative Medicine Co., Ltd. |
|
Ayako Nomori Business Development, manager |
Minaris Regenerative Medicine Co., Ltd. -Global CDMO company for focusing on Regenerative Medicine in Japan, US and Europe- |
| Presentation Stage C | October 13(Wed.) 10:55-11:10 |
|---|
| Megakaryon |
|
Dr. Makoto Satake Head of Business Development |
| Presentation Stage C | October 13(Wed.) 15:35-16:05 |
|---|
| [medU-net] Kansai Medical University |
|
Hirofumi Hitomi Professor, iPS Stem Cell Regenerative Medicine |
| Presentation Stage C | October 13(Wed.) 16:30-16:40 |
|---|
| PHCCorporation |
|
Togo Matsubara Coodinater |
Introduce MVE Fusion 1500TM |
| Presentation Stage E | October 13(Wed.) 11:30-12:00 |
|---|
| [medU-net] NIIGATA UNIVERSITY |
|
MAEKAWA Tomoki Graduate School of Medical and Dental Sciences Center for Advanced Oral Science , Associate Professor |
Development and deployment of regenerative therapeutics for inflammatory bone destruction and lung diseasesPeriodontitis and rheumatoid arthritis are characterized by the destruction of connective tissue and bone tissue with chronic inflammation, which progresses with aging and has a ... |
| Presentation Stage C | October 14(Thu.) 10:20-10:50 |
|---|
| Cytori Therapeutics, K.K. |
|
Momokazu Gotoh Japan Community Healthcare Organization Chukyo Hospital, Hospital Director |
Regenerative Medicine in the Treatment of Male Stress Urinary Incontinence with Autologous Adipose Derived Regenerative Cells |
| Presentation Stage C | October 14(Thu.) 11:15-11:25 |
|---|
| KYOKUTO PHARMACEUTICAL INDUSTRIAL |
Aiming to contribute to regenerative medicine |
| Presentation Stage C | October 14(Thu.) 11:30-12:00 |
|---|
| Minaris Regenerative Medicine Co., Ltd. |
|
Yoshifumi Yoshida Business Development, Head of Business Development |
Minaris Regenerative Medicine Co., Ltd. -Global CDMO company for focusing on Regenerative Medicine in Japan, US and Europe- |
| Presentation Stage C | October 14(Thu.) 12:20-12:30 |
|---|
| Sysmex corporation |
|
Chikage Yamamoto JEA R&I |
Introduce SYSMEX co.Introduce SYSMEX co. |
| Presentation Stage C | October 14(Thu.) 15:00-15:15 |
|---|
| Megakaryon |
|
Dr. Makoto Satake Head of Business Development |
| Presentation Stage E | October 14(Thu.) 15:35-16:05 |
|---|
| [medU-net] Yamaguchi University Graduate School of Medicine |
|
Taro Takami Professor, Department of Gastroenterology and Hepatology |
Our regenerative medicine and cell therapy initiatives at Yamaguchi UniversityAlthough the market for regenerative medicine and cell therapy is expected to grow, it is difficult for domestic universities, research institutes, and venture companies to ... |
| Main Stage A | October 15(Fri.) 12:30-13:00 |
|---|
| Forum for Innovative Regenerative Medicine |
|
Ikuo Kawauchi Chair, Standardization committee |
Development and utilize of standard towards industrialization of regenerative medicineThe Forum for Innovative Regenerative Medicine (FIRM) states in FIRM VISION 2025 that "FIRM works to industrialize regenerative medicine and disseminate innovative treatments". Utilization of ... |
| Main Stage A | October 15(Fri.) 13:00-13:30 |
|---|
| Forum for Innovative Regenerative Medicine |
|
Takeshi Nagaya Chair, Venture Establishment / Promotion Committee |
Venture Establishment / Promotion Committee Activity IntroductionFor the industrialization of regenerative medicine,the existence of bio-ventures that challenge the research and development of new technologies and innovative products is considered important,but the ... |
| Main Stage A | October 15(Fri.) 13:30-14:30 |
|---|
| Forum for Innovative Regenerative Medicine / Supporting Industry Committee |
|
Forum for Innovative Regenerative Medicine / Supporting Industry Committee |
Supporting Industry Committeeby the FIRM Supporting Industries Committee - Activities - Topics - Overview of 4 members company(Sartorius Stedim Biotech Japan, Nichirei Biosciences Inc. , PHC Holdings Corporation, Wanbishi ... |
| Main Stage B | October 13(Wed.) 13:10-13:20 |
|---|
| George and Shaun, Inc. |
|
Ken Inoue CEO |
Cognivida, an AI engine for estimating cognitive function in the elderly using lifestyle data, and corporate co-creation projectsFor about 4 years we have been developing Cognivida, an AI engine that estimates the cognitive function of the brain from everyday life information. Without using ... |
| Main Stage B | October 13(Wed.) 14:50-15:20 |
|---|
| Graduate School of Life and Medical Sciences, Doshisha University |
|
ICHIKAWA Hiroshi Professor |
Development of a method for preventing age-related diseases by inducing oxidative stress resistance by ultrasonic irradiationExposure to excessive oxidative stress is involved in the pathogenesis of aging-related diseases. In preventing these illnesses, it is essential to increase the antioxidative capacity ... |
| Presentation Stage C | October 13(Wed.) 10:20-10:30 |
|---|
| Evonik Japan |
|
Anatolio Pigliucci Health Care |
EVONIK: A market leader in CDMO service for formulation development and manufacturing of gene-based drugs and advanced nanomedicines |
| Presentation Stage D | October 13(Wed.) 14:25-14:55 |
|---|
| RIKEN / Biotec Co.,Ltd |
|
Rikiya Watanabe Chief Scientist |
| Main Stage B | October 14(Thu.) 15:20-15:30 |
|---|
| George and Shaun, Inc. |
|
Ken Inoue CEO |
Cognivida, an AI engine for estimating cognitive function in the elderly using lifestyle data, and corporate co-creation projectsFor about 4 years we have been developing Cognivida, an AI engine that estimates the cognitive function of the brain from everyday life information. Without using ... |
| Presentation Stage C | October 14(Thu.) 12:50-13:05 |
|---|
| Nagoya University |
|
Ikue Mori Graduate School of Science, Neuroscience Institute, Nagoya University, Director and Professor |
Pioneered approach in the improvement of aging societyEveryone desires eternally healthy life, and conversely fears aging and death. Nevertheless, scientists would say that humans are destined to die right after the birth. ... |
| Presentation Stage C | October 14(Thu.) 14:25-14:55 |
|---|
| Waseda University |
Activity change in the brain associated with pain reliefThe cause of chronic pain is unknown in many cases. This fact increases the use of complementary and integrative health approaches for pain. One of ... |
| Presentation Stage E | October 14(Thu.) 12:40-13:10 |
|---|
| [medU-net] TOYO UNIVERSITY |
|
Taira Kajisa Graduate School of Interdisciplinary New Science |
Construction of illuness prediction model by sensing data analysis using multi-monitoring deviceIn modern sports, the problem of breakdowns has been apparently increasing; thus, preventing injury and illness is needed. In addition, the number of mental illnesses ... |
| Presentation Stage E | October 14(Thu.) 14:05-14:20 |
|---|
| Nagoya University |
|
Shohta NAKAMURA Department of Thoracic Surgery, Lecturer |
Panorama vision ring that visualizes the entire body cavityThere is a need for innovative devices that can expand the surgical field of view and visualize what surgeon want to see, in this age ... |
| Presentation Stage E | October 14(Thu.) 15:00-15:30 |
|---|
| Frost & Sullivan Japan |
|
Nitin Naik |
Is Big Pharma Ready for 2022 & Beyond- Trends & Growth Opportunities |
| Main Stage B | October 15(Fri.) 11:20-11:30 |
|---|
| George and Shaun, Inc. |
|
Ken Inoue CEO |
Cognivida, an AI engine for estimating cognitive function in the elderly using lifestyle data, and corporate co-creation projectsFor about 4 years we have been developing Cognivida, an AI engine that estimates the cognitive function of the brain from everyday life information. Without using ... |
| Presentation Stage C | October 15(Fri.) 10:55-11:25 |
|---|
| [medU-net] Kumamoto University |
|
Yoshihito Kawamura |
Development of KUMADAI Magnesium Alloys for Medical ImplantsMagnesium alloys have attracted a great deal of attention for biomedical applications, such as medical implants, due to their high biodegradability. However, many scientific issues ... |
| Presentation Stage E | October 15(Fri.) 12:40-13:10 |
|---|
| Embassy of the Kingdom of the Netherlands & co-exhibitors (Presentation in English) |
Netherlands Life Science & Health - Presentation by Participating Companies |
| Presentation Stage E | October 15(Fri.) 13:15-13:45 |
|---|
| Tokyo Denki University |
|
Yukitoshi Nagahara Professor |
Effective skin moisture upregulator from inside your body, involving caspase-14 upregulationCaspase-14 is a type of an enzyme that maintains the barrier function and water retention function of the stratum corneum by degrading filaggrin, a structural ... |
| Presentation Stage E | October 15(Fri.) 14:25-14:55 |
|---|
| KOBE GAKUIN UNIVERSITY |
|
YOSHIMURA Yukihiro Faculty of Nutrition Associate Professor |
Skin application of sodium acetate and triacetin suppresses DNFB-induced allergic dermatitis.Topical steroids are widely used to treat allergic dermatitis. However, there are many patients who do not use steroids due to concerns about side effects, ... |
| Main Stage B | October 14(Thu.) 15:50-16:00 |
|---|
| NeoTechnology |
|
Sayuri Hashimoto Director |
The leading-edge of digital health from the perspective of patent information |
| Presentation Stage D | October 15(Fri.) 15:35-16:05 |
|---|
| [medU-net] St.Marianna University School of Medicine |
|
Toshiyuki Furukawa Division of Cardiology Dept. of Internal Medicine Associate Professor |
Applications to predict the syncopeTransient loss of consciousness, including syncope, is sudden onset and can lead to secondary trauma from falls or traffic accidents. Syncope is most commonly associated ... |
| Presentation Stage E | October 15(Fri.) 10:20-10:35 |
|---|
| Showa University |
|
Munakata Motohiro Department of Implant dentistry, Showa University Associate Professor |
Need for dental image identification software in super-aging society and construction of disaster victim identification systemGiven the progress of super-aging society, healthy life expectancy through dental services are demanded. However, large number of patients cannot benefit from proper dental treatment ... |
| Presentation Stage C | October 13(Wed.) 11:30-12:00 |
|---|
| [medU-net] FUJITA ACADEMY Fujita Health University |
|
Yamashita Takayuki Professor, School of Medicine |
Remote control of brain function using X-raysUnderstanding brain functions requires the perturbation of specific nerve cells in laboratory animals and the analysis of its consequences in behavioral and physiological processes. Perturbational ... |
| Main Stage A | October 14(Thu.) 15:35-15:55 |
|---|
| Hitachi High-Tech Science |
|
MASAKO ISHIMARU |
Application of rapid microbial testing by ATP method to pharmaceutical manufacturingMicrobial testing is a crucial inspection element when it comes to manufacturing safe pharmaceutical products. However, the conventional culture method requires several days for measuring ... |
| Presentation Stage C | October 14(Thu.) 11:05-11:15 |
|---|
| MIURA |
|
horikawa masahide medical equipment promotion management center /general manager |
| Presentation Stage D | October 14(Thu.) 12:40-13:10 |
|---|
| Bruker Japan |
|
Kazumi Tsukamoto Nano Surfaces and Metrology Division |
| Presentation Stage D | October 14(Thu.) 13:50-14:20 |
|---|
| Tokyo Denki University |
|
Yaguchi Toshiyuki Devision of Electronic Engineering, Associate Professor |
Microgravity floating culture using Aqueous two phase system for 3D cell tissue construction.The purpose of this study is to develop a cell-aggregates culturing system of using an aqueous two-phase system (ATPS) comprised of dextran and polyethylene glycol. ... |
| Presentation Stage E | October 14(Thu.) 13:15-13:45 |
|---|
| Nagoya University |
|
Shigeo Arai Professor |
Observation of the biological samples using high-performance electron microscopeNagoya University supports a molecular biologic study by a high voltage electron microscopy (HVEM) and excellent electron microscopes. These microscopes are very used by many ... |
| Presentation Stage D | October 14(Thu.) 14:40-14:55 |
|---|
| Institute of Transformative Bio-Molecules, Nagoya University |
|
Toshinori Kinoshita Institute of Transformative Bio-Molecules (ITbM) / Professor |
Promotion of Plant growth and Productivity by Controlling Stomatal ApertureStomata in plant epidermis open in response to light to induce CO2 uptake and transpiration. By contrast, stomata close in response to drought stress to ... |
| Presentation Stage C | October 13(Wed.) 16:10-16:20 |
|---|
| SAROUTE |
|
Genho Paku Life Science Innovation Div. Sales Group |
| Presentation Stage C | October 13(Wed.) 15:00-15:30 |
|---|
| UNION OF KANSAI GOVERNMENTS |
|
Tsuneaki Sakata,Ph.D.(Co-creation Bureau, Osaka University) Specially Appointed Professor |
Aim for the Bio-Community recognized by the world: the introduction of the life sciences industry in KansaiThe Union of Kansai Governments, consisting of eight prefectures and four cities designated by ordinance, is Japan's largest local public authority. In this presentation, we ... |
| Presentation Stage D | October 13(Wed.) 10:55-11:25 |
|---|
| Japan Patent Attorneys Association |
|
Hideo KOIKE |
Patent strategies of domestic and overseas biotech venturesWe have examined the patent strategies of domestic and overseas biotech ventures by categorizing them into four types: (1) cases in which the patenting of ... |
| Presentation Stage D | October 13(Wed.) 13:50-14:20 |
|---|
| Metropolitan Academic Research Consortium |
|
Mitsuyo Ohmura |
Metropolitan Academic Research Consortium (MARC) InitiativesIn order to accelerate the development of medical seeds from academia and deliver innovative medicines / medical devices in clinical practice, we established "Metropolitan Academic ... |
| Presentation Stage D | October 14(Thu.) 14:25-14:40 |
|---|
| Institute of Transformative Bio-Molecules, Nagoya University |
|
Masayasu Taki Institute of Transformative Bio-Molecules (ITbM) / Designated Associate Professor |
Organelle markers for long-term imaging of cellular dynamicsIn recent years, the development of various fluorescence microscopy techniques has enabled us to visualize the cellular dynamics with high spatiotemporal resolution. In order to ... |
| Presentation Stage D | October 14(Thu.) 15:00-15:30 |
|---|
| National Cancer Center Hospital/Japan Clinical Oncology Group: JCOG |
|
Keisuke KANATO Investigator, Research Management Division/Japan Clinical Oncology Group Operations Office |
| Main Stage B | October 15(Fri.) 14:45-15:45 |
|---|
| Social Health Strategy Research Institute |
|
Kenichiro Asano / Taketomo Watanabe |
| Presentation Stage E | October 15(Fri.) 15:35-16:05 |
|---|
| [medU-net] NIIGATA UNIVERSITY |
|
TASAKI Masayuki University Medical and Dental Hospital Urology, Assistant Professor |
A novel method measuring anti-ABO antibody titer by using kidney specific ABO glycoprotein antigen microarray -appropriate screening for ABO-incompatible kidney transplantation-ABO-incompatible kidney transplantation (ABOi KTx) which blood types are different between recipient and donor had been developed in Japan. Anti-ABO antibody can cause of antibody ... |
